CSS
APRE icon

Cubist Systematic Strategies’s Aprea Therapeutics APRE Stock Holding History

Cubist Systematic Strategies’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,029
Closed -$38K – 4349
2022
Q1 		$38K Buy
+1,029
New +$42.2K ﹤0.01% 3416
2021
Q1 		– Sell
-540
Closed -$53K – 2818
2020
Q4 		$53K Buy
540
+444
+463% +$211K ﹤0.01% 2464
2020
Q3 		$46K Buy
+96
New +$53.7K ﹤0.01% 2369

Other funds holding APRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Cubist Systematic Strategies's APRE Position: Q2 2022 in Review

Cubist Systematic Strategies sold out of Aprea Therapeutics (APRE) in Q2 2022, closing a stake of 1,029 shares — an estimated $38K sold.

Cubist Systematic Strategies first reported a position in APRE in Q3 2020 and held it in 3 quarters. The position peaked at $53K in Q4 2020. 33 funds tracked by Wall St. Rank hold APRE as of Q2 2022.

  • Cubist Systematic Strategies reported no remaining Aprea Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Cubist Systematic Strategies sold 1,029 Aprea Therapeutics shares in Q2 2022, an estimated $38K.
  • Cubist Systematic Strategies first reported a position in Aprea Therapeutics in Q3 2020 and held it in 3 quarters.
  • Cubist Systematic Strategies's Aprea Therapeutics position peaked at $53K in Q4 2020.
  • 33 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2022.

Based on Cubist Systematic Strategies's 13F filing for Q2 2022, filed 15 Aug 2022.